Northern Trust’s SOPHiA GENETICS SOPH Stock Holding History

Northern Trust’s Portfolio SOPH Stock Details SOPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,311	Closed	-$89K	–	4818
2021 Q4	$89K	Buy	+6,311	New	+$93.1K	﹤0.01%	4458

Other funds holding SOPH

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Northern Trust's SOPH Position: Q1 2022 in Review

Northern Trust sold out of SOPHiA GENETICS (SOPH) in Q1 2022, closing a stake of 6,311 shares — an estimated $89K sold.

Northern Trust first reported a position in SOPH in Q4 2021 and held it in 1 quarter. The position peaked at $89K in Q4 2021. 29 funds tracked by Wall St. Rank hold SOPH as of Q1 2022.

Northern Trust reported no remaining SOPHiA GENETICS position as of Q1 2022 after selling out during the quarter.
Northern Trust sold 6,311 SOPHiA GENETICS shares in Q1 2022, an estimated $89K.
Northern Trust first reported a position in SOPHiA GENETICS in Q4 2021 and held it in 1 quarter.
Northern Trust's SOPHiA GENETICS position peaked at $89K in Q4 2021.
29 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q1 2022.

Based on Northern Trust's 13F filing for Q1 2022, filed 13 May 2022.